Search the Newsreel

JPMorgan raises Annexon Biosciences price target on trial data By Investing.com

JPMorgan increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $15.00 from $14.00, maintaining an Overweight rating, based on the anticipated Phase 3 ARCHER II study results for vonaprument. The stock is currently trading at $4.08, implying a potential 267% upside, with key 15-month …

Insider Spends US$100k Buying More Shares In Annexon

Annexon's CEO, President & Director, Douglas Love, recently purchased US$100k worth of company stock. While this individual purchase signals confidence, the overall insider transaction history for the past year shows more selling than buying. Insiders collectively own 0.9% of Annexon shares, valued at US$6.2 …

Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares

Douglas Love, President and CEO of Annexon Inc (ANNX), recently purchased 26,065 shares of the company on September 24, 2026, increasing his total holdings to 390,476 shares. The transaction, valued at $3.83 per share, signals confidence from the executive in the clinical-stage biopharmaceutical company, …

After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares.

Annexon, Inc. President and CEO Love Douglas purchased 26,065 shares of common stock on September 24, 2026, at a weighted average price of $3.83 per share, bringing his direct holdings to 390,476 shares. The transaction, executed in multiple trades ranging from $3.815 to $3.829, …

More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings.

Annexon (ANNX) will present data from its vonaprument Phase 3 ARCHER II trial and a post hoc analysis of Phase 2 vision outcomes at The Retina Society's annual meeting on September 25, 2026. The presentations will cover baseline characteristics of participants in the ARCHER …

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon, Inc. announced two oral presentations at The Retina Society 59th Annual Scientific Meeting regarding vonaprument for geographic atrophy (GA). The presentations will highlight patient baseline characteristics from the Phase 3 ARCHER II trial and vision outcomes from the Phase 2 ARCHER trial, aiming …

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com

Annexon presented at the Cantor Fitzgerald Global Healthcare Conference, highlighting positive clinical data for its two late-stage neuroinflammatory disease programs. The company's lead eye drug, vonaprument, showed significant vision preservation in geographic atrophy, with an enrollment ahead of schedule for its Phase III ARCHER …

Annexon to Participate in Upcoming September Investor Conferences

Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in three upcoming investor conferences in September 2026. These include the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment …

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10

JP Morgan has increased its target price for ANNEXON, INC. shares from $10 to $14. This revision suggests an improved outlook from the financial institution regarding the company's future stock performance.

Annexon Biosciences Bets Big on Pivotal Trial Wins

Annexon Biosciences presented an optimistic outlook during its Q2 earnings call, highlighting significant clinical progress with tanruprubart for Guillain-Barré syndrome (GBS) and disciplined execution in geographic atrophy (GA) trials. The company also secured a non-dilutive credit facility, extending its cash runway into 2028. While …

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders

Annexon (ANNX) Institutional Ownership 2026

This article details the institutional ownership of Annexon (ANNX) as of 2026, providing data on institutional buyers and sellers, total inflows and outflows, and a list of major shareholders with their respective holdings and market values. It highlights that 105 institutional buyers invested $315.19M …

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - Margin Guidance

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - One-Time Gain Impact

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside

Annexon, Inc.'s average stock price target has been increased to $15.71 from $15 by 7 analysts, with forecasts ranging from $7 to $27 per share. This new target suggests a potential upside of approximately 198% based on the recent closing price. The consensus rating …

Annexon Inc (ANNX) Stock News Today

At $5.29, Annexon grants new employees options vesting over four years

Annexon (Nasdaq: ANNX) announced inducement grants of options to purchase 287,500 shares of common stock to three new non-executive employees. These options, granted at an exercise price of $5.29 per share, vest over four years, with 25% on the first anniversary and the remainder …

What is HC Wainwright's Estimate for Annexon Q3 Earnings?

Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Annexon (NASDAQ:ANNX) from a "sell" to a "strong sell" rating. This decision comes despite some other analysts maintaining "buy" or "hold" ratings for ANNX, with a consensus price target of $15.33. The company recently reported Q2 earnings, missing analyst …

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed

Annexon (ANNX) experienced a 6.1% decline in share price following the adoption of a dual primary endpoint in its ARCHER II trial for vonaprument, affecting its investment narrative. Despite a wider Q2 2026 net loss of US$55.35 million, the company secured up to US$200 …

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Annexon, Inc. announced an expansion of its vonaprument Phase 3 ARCHER II trial for geographic atrophy (GA), adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint. This strategy allows for success at either time point and will enable …

Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise

An individual affiliated with Annexon, Inc. (ANNX) has filed a Form 144 notice indicating an intent to sell 2,000 shares of common stock on August 13, 2026. These shares will be acquired through a same-day stock option exercise for cash. The filing also reports …

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27

This article provides an overview of Annexon (ANNX.US) stock ratings from four analysts in the last quarter, with a consensus price target ranging from $8 to $27. The analysts show a generally bullish sentiment, reflected in their diverse ratings and price targets, indicating varying …

Annexon (ANNX), What Is Behind Its Latest Update?

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in clinical, scientific, and corporate leadership to Annexon as it advances its late-stage clinical …

Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp

Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to …

Annexon shares fall 6% on wider-than-expected quarterly loss

Annexon (NASDAQ:ANNX) reported a second-quarter loss of $0.28 per share, which was wider than the analyst consensus of $0.24 per share, leading to a 6.37% fall in pre-market trading. The biopharmaceutical company attributed the increased loss to higher spending on its late-stage clinical programs, …

Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility

Annexon Releases Q2 2026 Financial Results

Annexon, Inc. (ANNX) reported a Q2 2026 basic and diluted loss per share of $0.28, an improvement from $0.34 in the prior year. The clinical-stage biopharmaceutical company posted a net loss of $55.3 million as it continues to invest in its pipeline for inflammatory-related …

Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS

Annexon (NASDAQ:ANNX) reported second-quarter earnings, missing analysts' consensus estimates by $0.05 with a loss of $0.28 per share. Despite the earnings miss, the company highlighted positive clinical trial data for tanruprubart in Guillain-Barré syndrome and expanded its ARCHER II geographic atrophy trial. Annexon also …

Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings